BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ariosa Diagnostics, Inc. Enters 2013 With New Offering and Global Expansion


1/9/2013 9:32:44 AM

SAN JOSE, Calif., Jan. 9, 2013 /PRNewswire/ -- Ariosa Diagnostics, provider of the Harmony Prenatal Test, today announced plans to expand the indications for the Harmony test and broaden access into new, significant global markets.

(Logo: http://photos.prnewswire.com/prnh/20121203/NE22396LOGO )

The Harmony test analyzes cell-free DNA circulating in maternal blood, which allows a high level of accuracy for detecting fetal trisomies, such as trisomy 21 that causes Down syndrome. Ariosa is expanding the clinical indications for the Harmony test to include all IVF singleton pregnancies, including unrelated egg donor and surrogate pregnancies.

The expanded Harmony test for IVF pregnancies will be available in the United States, as well as in several international markets. In 2012, Ariosa entered the European market as the first non-invasive prenatal test in the United Kingdom. Ariosa is now expanding throughout Europe, the Middle East, Australia, and Latin America.

"We are focused on identifying those test enhancements which can provide clear clinical utility," said Ariosa CEO Ken Song, MD. "The Harmony test represents a major clinical advance to provide reliable and accurate information to pregnant women, and we are committed to making this test available globally."

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.

SOURCE Ariosa Diagnostics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES